CONTACT US   |  (864) 397-5101

Afaxys Names Pamela Shepherd New Senior Vice President & Chief Financial Officer


Afaxys, LLC, a socially conscious healthcare company focused on serving patients in the community and public health system, announced today that Pamela (Pam) Shepherd, has been named Senior Vice President (SVP) and Chief Financial Officer (CFO). Shepherd will serve as Treasurer of the company, a member of the Executive Team and will oversee every aspect of financial management. Pam Shepherd succeeds Doug Hooper, SVP and CFO, who recently retired.

“Pam and I will work collaboratively to deliver on Afaxys’ short and long-term success, which includes building alliances and advancing development projects that expand access and strengthen our product offerings,” said Ronda Dean, President, CEO & Co-Founder of Afaxys, Inc. “Her comprehensive and multi-faceted financial experience spanning operations and investing, combined with her proven leadership in managing exponential growth will help us advance the mission and build long term value for the company. On behalf of the Board of Directors and my Executive Team, I would like to congratulate and welcome Pam to Afaxys.”

“I am excited to join Afaxys to ensure capital efficiency and margin optimization while also building shareholder value for this unique impact company,” said Shepherd.

Pam Shepherd was most recently managing director of Manna Tree Partners, a private equity firm dedicated to improving human health where she was responsible for investment underwriting and portfolio leadership. Prior to her role in private equity, Pam was the Chief Operating Officer and Chief Financial Officer of the Boppy Company, a global consumer products company dedicated to supporting mothers.

About Afaxys

Afaxys, whose name is derived from a combination of affordable and access, is a first-of-its-kind socially conscious healthcare company inspired by the need to solve a public health crisis. The organization uniquely partners with community and public health, and private industry to ensure healthcare providers have stable pricing and dependable access to the products and services they need to care for their patients.

The Afaxys enterprise is comprised of a family of companies that operate under two wholly owned subsidiaries: Afaxys Pharma, LLC and Afaxys Group Services, LLC (AGS). Afaxys Pharma provides a broad portfolio of branded and generic contraceptives to the public healthcare market. AGS is a strategic sourcing operation that negotiates favorable pricing across a broad base of products and services through its Group Purchasing Organization and emapp. For more information about Afaxys visit

Forward-Looking Statements

The statements in this press release that are not historical facts constitute “forward-looking statements” as defined by Federal Securities laws. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, risks related to the inability to implement strategic initiatives; and the dependence on key personnel. Forward-looking statements speak only as of the date they are made. Afaxys, Inc. will not update forward-looking statements to reflect factual assumptions, circumstances or events that have changed after a forward-looking statement was made.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.